Introduction
Fariborz Mansour-Ghanaei 1 *, Farahnaz Joukar 1 , Yaghoub Rajpout 2 , Tolou Hasandokht 3 Some experts in a 15 year trend analysis showed a steady pattern for gastric cancer in Guilan province. They also reported the age standardized incidence rate was 14.5 per 10 5 (Atrkar-Roushan et al., 2013) . The diagnosis of gastric cancer is usually late and thus, its prognosis is very poor (Maconi et al., 2008) . In most areas of the world, except in Japan, Overall 5-year survival rates, estimate 20% (Cunningham et al., 2005; Ries et al., 2008) . Mass screening programs, staging systems in Japan, would help to achieve 5-year survival rates of approximately 60% (Tsubono and Hisamichi, 2000; Parkin et al., 2002) . In the diagnosis of atrophic gastritis and premalignant lesions, and also in the differentiation between healthy and diseased stomach mucosa, two options are available. Upper gastrointestinal (GI) endoscopy and histological examination of endoscopic biopsy is the first option. The second non-invasive option, is the examination of some serum markers, such as pepsinogen (PG I), pepsinogen I/II ratio (PG I/II ratio) and gastrin 17 (G-17) (Borch et al., 1989; Karnes Jr et al., 1991) . Gastric PG I and PG II are produced by the chief and mucus neck cells in the gastric fundus. But, only, PG II is produced by the pyloric glands in the antrum and Brunner's glands.as a result of inflammation, both pepsinogen elevated and then, as atrophic gastritis progress the concentration of PGII remains increased, while the concentration of PGI decreases. Consequently, the changes in pepsinogen may reflect the morphological status of the gastric mucosa (Foltmann, 1981) .
In recent years, the usefulness of the serum PG I and PG I/II ratio, G-17 and H pylori antibodies (HpAb) has been investigated to early diagnose chronic gastric atrophy and for screening gastric cancer in some developed countries, including Europe and Japan (Sipponen et al., 2002; Vaananen et al., 2003; Ohata et al., 2004; Shiotani et al., 2005) .
The aim of present study was to assess the serum tests: serum PGI, PG I/II ratio, G-17, H Pylori-IgG antibodies and Anti Cag A in precancerous lesions and nonatrophic chronic gastritis in patients with dyspepsia who had been diagnosed by Gastroscopy and biopsy.
Materials and Methods
We designed a cross sectional study to compare the serum gastric markers in precancerous lesions and nonatrophic chronic gastritis on 128 patients over 50 years old with dyspepsia between June 2013 to November 2013.The Medical Ethics Committee of Guilan University of Medical Sciences (GUMS) has approved the study design, protocols and informed consent procedure. This study was funded by Gastrointestinal and Liver Disease Research Center (GLDRC) of Guilan University of Medical Sciences.
Participants were recruited from GLDRC out patient clinic or private office. According to the inclusion and exclusion criteria, a total of 128 subjects with dyspepsia or epigastric pain who underwent endoscopy were divided into two groups based on endoscopic and histological findings: 40 patients in the precancerous (metaplasia, dysplasia, neoplasia and atrophic gastritis) group and 88 (including non atrophic gastritis) served as the control group. Patients over 50 years with any kind of dyspepsia willing to provide informed consent for study participation were included. Exclusion criteria were the following: history of gastric surgery, prior H pylori eradication therapy, serious systemic disease such as Renal failure or liver disease, and those taking anti secretory or proton pump inhibitors four (4) weeks prior to the present study and anti-coagulant drugs or any condition which might have a negative effect on the compliance of the participants. Endoscopic and histological examinations before the serum tests, each subject underwent endoscopy. Subsequent two local anesthesia using Lidocaine 10% (with 10 minute interval) upper GI endoscopy (videoendoscope, GIF-Q240Z; Olympus Co., Tokyo, Japan) was performed by three experienced endoscopists and cooperation of a trained staff based on the standard guideline to decrease observer bias. Three samples were taken from different parts of stomach (body, fundus, antrum) and one sample from antrum for RUT to detect H Pylori infection. The samples were fixed in formalin 10%, labeled by subjects' codes and described by a blinded pathologist.
To decrease measurement bias, all blood samples were analyzed in a single private laboratory. The 5 cc blood samples were taken after overnight fasting for measurement serum gastric markers.Determination of serum levels of PGI, PGII and G-17 was performed using a commercial ELISA assay (Gastropanel ® ; (BioKit ® , Helsinski, Finland), following the manufacturer's instructions. Anti-H Pylori IgG and anti-cag A antibody were analyzed by ELISA method ((Pishtaz teb Co. Iran and Diapro Kits) All descriptive statistics are presented as mean (standard deviation (SD)) for quantitative variables or number (%), for categorical variables. To compare total premalignant lesion with nonatrophic gastritis, we created a new group named precancerous lesion consist of metaplasia, dysplasia, neoplasia and atrophy.
Two-sample t-tests were used for the comparison of continuous variables and Pearson's chi-square tests were used for the comparison of categorical variables. The Pearson correlation analyses were used to study the bivariate relationships between serum gastric markers and gastric lesions.Statistical analysis was carried out with the SPSS (version 20) and p<0.05 was considered statistically significant.
Results
A total of 128 patients (71 women, 55%) with an average age of 66.5 years were included. The two most common symptoms were epigastric pain and dyspepsia. Endoscopy was compatible with nonatrophic chronic gastritis in 120 patients, showed dysplasia in 5 patients, metaplasia in 39 patients and neoplasia in 6 patients. H pylori infection based on the serologic test was positive in 55% (71) of participants. The distribution of nonatrophic chronic gastritis and precancerous lesions in both sexes were similar (Table 1) .
The percentage of low, normal and high serum PGI and PGI/PGII ratio were significantly different in patients with precancerous lesions to chronic gastritis (p=0.005, 0.03, respectively). Furthermore, the frequency of positive H pylori IgG patient was significantly (p=0.03) different between chronic gastritis and precancerous lesion groups ( Table 2) .
The mean value of PGI and PGI/PGII ratio were 
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significantly different in patients with precancerous lesions to nonatrophic chronic gastritis (p=0.05, 0.001, respectively). There was no statistically significant difference in the mean value of PGII, G-17 and anti CagA between precancerous lesion and non atrophic gastritis (Table 3) .
Bivariate relationships were determined between some serum gastric marker and gastric lesions. PGI and PGI/ PGII ratio was significantly correlated with precancerous lesions (p<0.05). There was no significant correlation between
Discussion
The results of our study showed that the frequency of reduced PGI and PGI/PGII ratio was more common in patients with precancerous lesions. Those who had any of the premalignant histologic gastric lesions (metaplasia, neoplasia and dysplasia) have been reported the lower mean value of PGI and PGI/PGII. Ratio, urthermore, we detected the mean value of PGI and PGI/PGII ratio were significantly lower in patients with precancerous lesion than nonatrophic gastritis. This finding coheres with the results of a large-scaled study in the hot point regions of Iran for GC designed to assess prognostic value of screening biomarkers like pepsinogen I/II and G17 (Shafaghi et al., 2012) . In this study, Shafaghi et al present the cut off value of PGI<90.6ng/ml with the sensitivity and specificity of 64.7% and 40% respectively for any of three lesions (metaplasia, dysplasia or atrophy). Qin CAO et al described serum PGI and PGI/PGII level decreased in atrophic gastritis and gastric cancer groups. In a 10 years follow up of 5, 209 asymptomatic subjects, Yanaoka et al. (2008) showed gastric cancer risk increased with a reduced serum PG I level or a reduced PG I/II ratio.
In our study, the serum gastrin level were similar in patients with precancerous lesions and nonatrophic chronic gastritis. Sheykholeslami et al find neither PGI, the PG I:II ratio, gastrin 17, nor their combination were able to predict precancerous conditions among the first-degree relatives of gastric cancer patients (Haj-sheykholeslami  et al., 2008) . Similarly, a case control study in Peru reported serum gastrin-17 can not be considered as a useful screening marker in early detection of gastric cancer (Colarossi et al., 2010) . On the other hands, some previous researches showed that low levels of serum G-17 in combination with low serum PGI or PGI/PGII ratio identifies patients with advanced and extensive atrophic gastritis in both the antrum and corpus (Karnes Jr et al., 1991; Vaananen et al., 2003) . While, in other research, the increased serum Gastrin was found to be as a marker for advanced corpus atrophy (Sipponen et al., 2002) . Furthermore, Shafaghi et al. (2012) reported the serum G-17 might be a good biomarker for gastric atrophy or metaplasia. In this area, Zhang et al. (2007) described in a large sample mass screening study, the serum gastrin level can be elevated in the precancerous stage of gastric cancer, but can be significantly reduced on the onset of the formation of gastric cancer. Some probable reasons for this discrepancy are: the serum Gastrin content can be influenced by many factors, such as age, lesion sites, disease types and H Pylori infection.
Our study indicated that the frequency of H pylori IgG were different between chronic gastritis and precancerous lesions groups. This finding was confirmed by some previous researches which have been reported serum anti H pylori and pepsinogens were found to be useful in distinguishing subjects with non-atrophic gastritis from those with normal mucosa (Vaananen et al., 2003; Germana et al., 2005) . Another studyshowed H Pylori can increase the serum gastrin level; and the elevation of serum gastrin level by H Pylori may be one of its carcinogenic mechanisms (Gisbert et al., 1996) .
In our study, the frequency of anti cag A was similar in precancerous and chronic gastritis groups. Although, Backert et al. (2009) indicated a significant association of cag PAI presence with histopathological findings in gastritis, peptic ulcer, and gastric cancer patients. Recently, researcher found that, the cag PAI appeared not to be useful predictor for H Pylori-related diseases in Iranian patients (Baghaei et al., 2009; Jafarzadeh et al., 2009 ).
An important aspect of the current study refers to compare the serum gastric markers in precancerous patients with nonatrophic chronic gastritis. While, majority of previous studies tried to assess the gastric biomarkers ability to predict gastric cancer or to compare serum gastric level between healthy people and patients with precancerous lesions or gastric cancer. Our result confirmed our previous finding suggested serum PGI and PGI/II ratio screening can detect premalignant lesions (Shafaghi et al., 2012) .
Our study, while having much strength, involved a limitation that should be considered. We can not assess the serum gastric markers in two groups of study regard to location of the lesion because of small sample size in each group. So, further research with larger sample size in every group were required.
In conclusion, analyses of serum PGI and PGI/II ratio offer important information regarding the presence of premalignant gastritis lesions and provide a useful marker for screening gastric disease. Serum pepsinogen could be recommended as a first step to dyspeptic patients who have no alarming symptoms. 
